Precision Cell Systems (PCS) has acquired BennuBio to enter the 3D cell culture market.
The acquisition brings BennuBio’s Velocyt imaging flow cytometer into the PCS portfolio, expanding the company’s capabilities in single-cell analysis, cell therapy, drug discovery, and bioprocessing applications.
BennuBio is a New Mexico-based life science company that has developed an imaging flow cytometer for high-throughput analysis of 3D multicellular models including spheroids, organoids, and stem cell aggregates. The Velocyt platform addresses a critical unmet need by rapidly characterising large particles beyond the capabilities of standard flow cytometry while enabling complete sample recovery for downstream analysis.
“The next wave of therapies will rely on complex 3D cell models, but the analytical tools have lagged behind,” said Anup Parikh, CEO of Precision Cell Systems.
“BennuBio’s technology allows researchers to rapidly analyze intact samples at scale and then recover them for further analysis, kinetic studies, or continued growth. This acquisition positions PCS to deliver a seamless workflow that connects complex 3D models with single-cell insights.”
“The Velocyt has allowed us to study nanoparticle uptake and immune cell penetration in intact cancer spheroids at an unprecedented scale. In just minutes, we can evaluate hundreds of thousands of multicellular clusters and recover them intact for downstream analysis. This technology is transforming how we approach complex 3D tumour biology,” said Rita Serda, associate professor at the University of New Mexico Comprehensive Cancer Center and Velocyt customer.
“I’m incredibly proud of the progress our team made in advancing 3D multicellular analysis,” said John O’Rourke, former CEO of BennuBio.
“Joining PCS provides the operational scale and workflow integration needed to realize the full potential of this technology and accelerate its impact for researchers globally.”
O’Rourke will join PCS along with BennuBio co-founder Travis Woods to lead the integration and continued development of the Velocyt platform. The acquisition also strengthens PCS’s financial position with the addition of Tramway Ventures, BennuBio’s lead investor, to its syndicate.
This marks PCS’s third acquisition in 2025, following the additions of S2 Genomics and ORFLO.
The company is actively pursuing additional acquisitions, targeting complementary technologies for sample preparation, functional cellular and molecular assays, to build a cell analysis workflow platform.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
